Novo Nordisk Diagrams Response To FDA GMP Warning Letter
This article was originally published in The Pink Sheet Daily
The warning letter says Novo Nordisk’s initial response to findings of a March 2012 FDA inspection lack sufficient corrective action; the firm says it has responded to FDA’s concerns and that the letter should not impact any products marketed in the U.S.
You may also be interested in...
Quanta Dialysis is linking up with B. Braun Avitum UK to support patients with Quanta’s personal hemodialysis device in the home. See what Quanta CEO John Milad said about it here.
Cosmetics Europe’s Director-General John Chave discusses next steps in the European Union’s proposed drive to ban manufactured microplastic in all cosmetic products. Industry continues to fight for something more proportionate, but it’s up against powerful forces in today’s European theater.
HanAll and Daewoong remain upbeat on dry eye candidate HL036 and are gearing up for a second Phase III US study despite the first missing its primary endpoint in just-released top-line results.